Advanced Search

 

Study ID Status Title Patient Level Data
VRX-RET-E22-108 Completed A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-301 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-302 Completed Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-303 Completed A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)
VRX-RET-E22-MR103 Completed Open-Label Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Retigabine Following Single and Multiple Dose Administration of Two Different Modified Release Formulations Compared to Single Dose Administration of One Immediate Release Formula Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-NP201 Completed A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia Study Listed on ClinicalStudyDataRequest.com
W2650782 Completed A pharmacokinetic study of two oral formulations of orlistat
W2651062 Completed A Study to Assess the Pharmacodynamic Equivalence of Two Orlistat Dosage Forms
W3600586 Completed The effects of weight reduction with orlistat vs. placebo on changes in body composition
W3680604 Completed A study to assess the pharmacologic equivalence of two orlistat dosage forms
W3730613 Completed A Dose-Ranging Study of a Tablet Formulation of Orlistat
W5350856 Completed Survey on the pharmacy follow up of Alli purchasers
W7781293 Completed An Exploratory Study to Measure the Effect of Two Dietary Fibers on Satiety and Glycemic Parameters
W91-016 Completed The Pharmacokinetics and Tolerability of Ondansetron 4mg Given as an Intramuscular Injection
WELL 029 Completed Multicenter Evaluation of the Efficacy and Safety of Low Doses of Wellbatrin vs. Placebo in Depressed Inpatients
Well 08 Completed Phase II Placebo-Controlled Evaluation of Efficacy: Multiclinic Study
WELL 203 Completed A Multicenter Evaluation of the Safety and Efficacy of 150mg/day and 300mg/day of Bupropion HCl Sustained-Release Versus Placebo in Depressed Outpatients
WELL 205 Completed A multicenter dose-response evaluation of the safety and efficacy of bupropion HCI sustained-release versus placebo in depressed outpatients
WELL 208 Completed Safety Surveillance Study for WELLBUTRIN® (bupropion hydrochloride) Sustained Release
Well 209 Completed The Safety and Efficacy of Wellbutrin Sustained Release and Sertraline in Depressed Outpatients
WELL 212 Completed A multicenter evaluation of the safety and efficacy of two flexible doses of WELLBUTRIN sustained-release versus placebo in depressed outpatients
Well 41 Completed A Single-Blind Pilot Study of the Safety and Efficacy of Wellbutrin in Children with Attention Deficit and/or Conduct Disorders
Well 84A Completed Multicenter evaluation of the efficacy and safety of a 300 mg daily dose of Wellbutrin versus placebo in depressed outpatients
Well 86A Completed Prospective open evaluation of the seizure incidence with bupropion hydrochloride (Wellbutrin®)
Wellbutrin 06 Completed Phase II Placebo-Controlled Proof of Efficacy, Multi-clinic Study

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.